MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritis

Juvenile Idiopathic Arthritis

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

Rheumatology (Oxford).

Heiligenhaus A, Klotsche J, Tappeiner C, Sengler C, Niewerth M, Liedmann I, Hoeft S, Walscheid K, Lavric M, Foell D, Minden K

doi: 10.1093/rheumatology/key406.

Juvenile Idiopathic Arthritis

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis

Arthritis Care Res (Hoboken).

Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML, Colbert RA, Feldman BM, Holland GN, Ferguson PJ, Gewanter H, Guzman J, Horonjeff J, Nigrovic PA, Ombrello MJ, Passo MH, Stoll ML, Rabinovich CE, Sen HN, Schneider R, Halyabar O, Hays K, Shah AA, Sullivan N, Szymanski AM, Turgunbaev M, Turner A, Reston J

doi: 10.1002/acr.23871.

Juvenile Idiopathic Arthritis

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Arthritis Res Ther.

Horneff G, Schulz AC, Klotsche J, Hospach A, Minden K, Foeldvari I, Trauzeddel R, Ganser G, Weller-Heinemann F, Haas JP

doi: 10.1186/

Juvenile Idiopathic Arthritis

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Ann Rheum Dis.

Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ

doi: 10.1136/annrheumdis-2018-213150.

Juvenile Idiopathic Arthritis

Dynamic contrast-enhanced magnetic resonance imaging can play a role in predicting flare in juvenile idiopathic arthritis

Eur J Radiol.

Nusman CM, Hemke R, Lavini C, Schonenberg-Meinema D, van Rossum MA, Dolman KM, van den Berg JM, Maas M, Kuijpers TW

doi: 10.1016/j.ejrad.2017.01.003.

Juvenile Idiopathic Arthritis

Ultrasound changes in synovial abnormalities induced by treatment in juvenile idiopathic arthritis

Clin Exp Rheumatol

Lanni S, van Dijkhuizen EHP, Vanoni F, Viola S, Magnaguagno F, Magnano GM, Gandolfo C, Ravelli A, Malattia C

Juvenile Idiopathic Arthritis

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Arthritis Care Res (Hoboken).

Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, Rygg M, Toftedal P, Nielsen S, Fasth A, Berntson L, Nordal E, Herlin T, Nordic Study Group of Pediatric Rheumatology (NoSPeR)

doi: 10.1002/acr.23853.

Juvenile Idiopathic Arthritis

Treatment Satisfaction with and Adherence to Disease-Modifying Antirheumatic Drugs in Adult Patients with Juvenile Idiopathic Arthritis

Arthritis Care Res (Hoboken).

Tollisen A, Flatø B, Selvaag AM, Aasland A, Ingebrigtsen T, Sagen J, Lerdal A

doi: 10.1002/acr.24113.

Juvenile Idiopathic Arthritis

Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA)

Ann Rheum Dis.

De Lucia O, Ravagnani V, Pregnolato F, Hila A, Pontikaki I, Gattinara M, Romano M, Gerloni V, Pieropan S, Murgo A, Rossini M, Cimaz R, Meroni PL

doi: 10.1136/

Related content

Predictive factors and biomarkers for the 2-year outcome of uveitis in juvenile idiopathic arthritis: data from the Inception Cohort of Newly diagnosed patients with Juvenile Idiopathic Arthritis (ICON-JIA) study

2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis

Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials

Dynamic contrast-enhanced magnetic resonance imaging can play a role in predicting flare in juvenile idiopathic arthritis

Ultrasound changes in synovial abnormalities induced by treatment in juvenile idiopathic arthritis

Long-term outcomes in juvenile idiopathic arthritis: 18 years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis (JIA) cohort

Treatment Satisfaction with and Adherence to Disease-Modifying Antirheumatic Drugs in Adult Patients with Juvenile Idiopathic Arthritis

Baseline ultrasound examination as possible predictor of relapse in patients affected by juvenile idiopathic arthritis (JIA)